Merck recalling VAQTA hepatitis A vaccine
February 1, 2002 less than 1 minute read
Merck recalling VAQTA hepatitis A vaccine
Merck & Co., Inc. is voluntarily recalling specified lots of VAQTA (hepatitis A vaccine, inactivated) in prefilled syringes. Re-tests of VAQTA have revealed a decreased antigen content in some syringes below the established minimum specification. As a result, a possibility exists that persons vaccinated with VAQTA in prefilled syringes from the indicated lots may be insufficiently protected against hepatitis A.
Patients who may have received doses from the indicated lots would have been vaccinated after May 29, 2001, with the adult formulation (50 U/1 mL), and after Aug. 9, 1999, with the pediatric/adolescent formulation (25 U/0.5 mL). Guidelines for antibody testing and revaccination of these patients are available. See the "Dear Healthcare Professional" letter for more details located on the web: www.fda.gov/medwatch/SAFETY/2001/safety01.htm#vaqta.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content